Pharmafile Logo
Pharmafocus logo
Advanced Search

Xarelto

Showing 15 posts of 74 posts found.

janssen_latest_logo_on_sign_closer

FDA approves Janssen’s Xarelto for blood clot prevention

October 15, 2019
Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism

Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …

News

Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease

August 1, 2019
Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma

NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …

News
shutterstock_512649

J&J joins in on industry price hiking; almost 500 drug prices increased in 2019 so far

January 11, 2019
Medical Communications, Sales and Marketing J&J, JJ, Stelara, US, Xarelto, Zytiga, pharma, price hikes

It’s only the second week of the New Year, and Johnson & Johnson has announced plans to hike the prices …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes

The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …

News
xarelto_10_tablet1

Bayer and J&J successfully reverse $28 million Xarelto court payout

January 10, 2018
Research and Development, Sales and Marketing Bayer, J&J, JJ, Johnson & Johnson, Xarelto, pharma

Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …

News
bayer_cross_2

Bayer forced to halt huge study into key drug

October 6, 2017
Medical Communications, Research and Development Bayer, Janssen, Xarelto, biotech, drugs, pharma, pharmaceutical

Bayer, and development partner Janssen, have been forced to stop a Phase 3 trial looking at expanding the indication of …

News

Bayer’s cardiovascular drug races to target in trial

February 9, 2017
Research and Development, Sales and Marketing Bayer, Janssen, Xarelto

Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …

News
janssen_stairs_1

Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial

September 29, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …

News
credit_bayerag

Bayer’s earnings beat estimates as blockbusters shine

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales

Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …

News
Xarelto

Investigation questions Xarelto trial data accuracy

February 4, 2016
Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …

News
Xarelto

Bayer backs safety of Xarelto after real-world data study

September 2, 2015
Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban

Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …

News
Xarelto image

Bayer promotes Xarelto benefits

June 15, 2015
Sales and Marketing Bayer, Eliquis, Xarelto, blood, law suits, rivaroxaban

Bayer HealthCare is releasing new evidence to suggest that the risk of taking its best-selling blood thinner Xarelto is outweighed …

News
china_flag

Chinese government to lift drug price controls

May 5, 2015
Sales and Marketing China, Drug pricing, GSK, IMS, Xarelto, government

The Chinese government has announced that it will remove price caps for most medicines and allow the market to play …

News
bayer_chimney

Bayer buys blood-thinning drug from Isis

May 5, 2015
Research and Development, Sales and Marketing Bayer, Eliquis, ISIS-FXI, Isis, Xarelto, blooding thinning

German drug giant Bayer is sealing a $155 million deal with Isis Pharmaceuticals to gain access to its anti-clotting treatment …

News
Bayer image

Profits fall at Bayer but new drugs see growth

May 1, 2015
Sales and Marketing Bayer, Eliquis, Eylea, Renegeron, Xarelto, apixaban

Bayer’s pharmaceutical revenues have continued their upward trajectory in the first quarter of 2015 thanks to new products, although this …

News

Latest content

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023

British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing

December 5, 2023

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023

Dr Stefano Gulià appointed as chief scientific officer of Kling Bio

December 5, 2023